Stryker Co. (NYSE:SYK) Shares Bought by Dillon & Associates Inc.

Dillon & Associates Inc. increased its position in Stryker Co. (NYSE:SYK - Free Report) by 2.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 86,293 shares of the medical technology company's stock after acquiring an additional 1,819 shares during the period. Stryker makes up about 4.4% of Dillon & Associates Inc.'s portfolio, making the stock its 6th biggest holding. Dillon & Associates Inc.'s holdings in Stryker were worth $31,152,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in SYK. Patrick M Sweeney & Associates Inc. lifted its stake in shares of Stryker by 1.5% in the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company's stock valued at $793,000 after purchasing an additional 32 shares during the period. Versant Capital Management Inc grew its holdings in Stryker by 4.0% in the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company's stock valued at $294,000 after purchasing an additional 33 shares during the period. Stanley Laman Group Ltd. increased its position in shares of Stryker by 4.6% in the second quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company's stock valued at $256,000 after buying an additional 33 shares in the last quarter. Plimoth Trust Co. LLC raised its stake in shares of Stryker by 0.3% during the 2nd quarter. Plimoth Trust Co. LLC now owns 9,476 shares of the medical technology company's stock worth $3,224,000 after buying an additional 33 shares during the period. Finally, Grimes & Company Inc. grew its stake in Stryker by 0.4% in the 3rd quarter. Grimes & Company Inc. now owns 8,239 shares of the medical technology company's stock valued at $2,977,000 after acquiring an additional 33 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on SYK. Wolfe Research assumed coverage on shares of Stryker in a report on Tuesday, September 10th. They set an "outperform" rating and a $405.00 price objective on the stock. BTIG Research increased their price objective on Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Evercore ISI increased their target price on shares of Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Citigroup upped their price objective on shares of Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Finally, Canaccord Genuity Group raised their target price on shares of Stryker from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $393.65.

Insiders Place Their Bets

In related news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Viju Menon sold 600 shares of Stryker stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares of the company's stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock worth $24,825,275 over the last 90 days. Corporate insiders own 5.90% of the company's stock.

Stryker Trading Up 0.5 %

Shares of NYSE SYK traded up $2.08 during trading on Wednesday, reaching $389.19. The stock had a trading volume of 747,603 shares, compared to its average volume of 1,252,637. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company has a market cap of $148.37 billion, a P/E ratio of 41.47, a PEG ratio of 2.92 and a beta of 0.91. Stryker Co. has a fifty-two week low of $282.35 and a fifty-two week high of $390.59. The business's 50-day moving average price is $362.38 and its 200-day moving average price is $346.42.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker's revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.46 EPS. On average, equities research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.